Bioaffinity Technologies, Inc. current report, Q2 FY2025

Full document

Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 5, 2025, details a material definitive agreement and equity financing event for Bioaffinity Technologies, Inc. The Company, an emerging growth company incorporated in Delaware, consummated a best efforts public offering on May 7, 2025. The filing covers the entry into a Securities Purchase Agreement and a Placement Agency Agreement to raise capital for working capital and general corporate purposes.

Key Financial Metrics and Offering Details

  • Gross Proceeds: Approximately $3.2 million.
  • Securities Issued:
    • 7,784,904 shares of Common Stock.
    • 2,371,346 Pre-Funded Warrants (exercisable for Common Stock).
    • 15,234,375 May 2025 Warrants (150% of shares and pre-funded warrants sold).
  • Offering Prices:
    • Common Stock + May 2025 Warrant: $0.32 per unit.
    • Pre-Funded Warrant + May 2025 Warrant: $0.313 per unit.
  • Transaction Costs:
    • Placement Agent Fee: 8.0% of gross proceeds.
    • Expense Reimbursement: $120,000 paid to WallachBeth Capital LLC.
    • Placement Agent Warrants: 304,687 warrants issued (3.0% of aggregate shares/pre-funded warrants).
  • Outstanding Shares: 27,249,462 shares of Common Stock outstanding as of the filing date (post-offering and partial pre-funded warrant exercise).

Material Changes and Agreements

The Company entered into a lock-up agreement restricting the issuance of Common Stock or equivalents for 60 days post-closing and prohibiting variable rate transactions for 12 months. Executive officers and directors are subject to a 60-day lock-up on their existing securities. The May 2025 Warrants include a "Reverse Stock Split Adjustment" (30% increase in shares if a reverse split occurs) and an "Anti-Dilution Adjustment" (price reset to the lowest price in subsequent offerings, subject to a $0.10 floor and stockholder approval).

Outlook, Risks, and Contingencies

  • Use of Proceeds: Working capital and general corporate purposes.
  • Dilution Risk: The May 2025 Warrants contain significant anti-dilution provisions. If a "Dilutive Issuance" occurs, up to 49,907,811 additional shares could be issuable upon exercise (subject to adjustments and stockholder approval).
  • Exercise Restrictions: Holders are limited to beneficial ownership of 4.99% (or 9.99% with notice) of outstanding shares immediately after exercise.
  • Regulatory Requirements: Full exercise of anti-dilution provisions requires stockholder approval and an amendment to the Certificate of Incorporation to increase authorized shares to 350,000,000.

Investor Verification Checklist

  • Verify the net proceeds after deducting the 8.0% placement fee and $120,000 expense reimbursement.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the 60-day lock-up and 12-month variable rate prohibition.
  • Assess the potential dilution impact of the May 2025 Warrants, specifically the Anti-Dilution Adjustment and Reverse Stock Split Adjustment clauses.
  • Confirm the timeline for the required stockholder vote to approve the Certificate of Amendment for the anti-dilution provision.
  • Monitor the Company's cash burn rate relative to the $3.2 million gross proceeds to determine runway for operations.